Name Surname The Board of Directors of Fine Foods & Pharmaceuticals N.T.M. S.p.A. today approved the Group's Interim Financial Report as of 30 September 2023.

Company Consolidated revenue +21.5% and EBITDA +51.2% in the first nine months of 2023

Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il The Food (+29.2%) and Pharma (+26.9%) BUs drive the Group's growth. Fine Foods' margins show a recovery compared to the first nine months of 2022.

invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat.

Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum Highlights

Role

facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet dercill itiatem cum que doluptur • Consolidated Revenue in 9M 2023 was € 185.7 million, up 21.5% from € 152.8 million in the same period of 2022.
magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic • EBITDA for the period was € 18.3 million and showed an increase of 51.2% compared to € 12.1 million in the same period of 2022. Adjusted EBITDA for the period corresponds to EBITDA. In 9M 2022, adjusted EBITDA was € 12.6 million.
ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni tem etum laborat estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt, simus. Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. • EBITDA Margin in 9M 2023 was approximately 10%, up from 7.9% in the same period of 2022. Adjusted EBITDA margin corresponds to EBITDA margin. In 9M 2022, the Adjusted EBITDA Margin was 8.2%.
Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur? Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin • Operating result (EBIT) as of 30 September 2023 was € 2.2 million compared to € 1 million in 2022. Adjusted EBIT for the period was € 6.6 million compared to € 1.4 million in the same period of 2022.
cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus • The Result for the Period was € -1.8 million (€ -11.9 million as of 30 September 2022). The Adjusted Result for the Period, net of the impairment carried out on goodwill, was positive € 2.6 million (€ - 11.6 million as of 30 September 2022).
plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same • The Group's Net Financial Position as of 30 September 2023 was € 53.6 million, compared to € 43.6 million as of 31 December 2022.

***

vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil id moluptatur. endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime eum quo qui quas aut ant ut laborporae. Ut porum et optates mi, ommolor eperit quiassequid Verdellino (Bergamo, Italy), 14 November 2023 - The Board of Directors of Fine Foods & Pharmaceuticals N.T.M. S.p.A. - an Italian independent Contract Development & Manufacturing Organisation (CDMO) that develops and manufactures contract products for the pharmaceutical, nutraceutical, and cosmetics industries, listed on Euronext STAR Milan (ticker: FF), approved the Interim Financial Report as of 30 September 2023.

earunde lluptate ditatur am ut qui as ut laut ditem laborporio molorem saperessi omnissusciis dolut magnihil ini corerro es niscia natem reri qui soloratistis velita quam volo quo el et alit The first nine months of 2023 showed Consolidated Revenues of € 185.7 million, with an increase of 21.5% compared to € 152.8 million in the same period of 2022.

harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci. Food Business Unit revenues in the first nine months of 2023 were € 111.5 million compared to € 86.4 million in the previous period with an increase of 29.2%.

Name Surname The Pharma Business Unit reconfirmed its turnover increase, reaching € 50.80 million in 9M 2023. This represented an increase of 26.9% compared to the same period in the previous year.

Role Company The contribution of the Cosmetic Business Unit in 9M 2023 was € 23.4 million, down from € 26.5 million in the same period of 2022. This was generated by the disposal of non-strategic business lines and the ongoing restructuring of operations.

invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum Although the 2023 results are compared to 2022, a year strongly impacted by the energy and supply chain crisis, we are proud of the strong margin recovery, which is the result of an increasingly solid and reliable organisation.

facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a In the second half of 2023 we saw the first positive signs in the Cosmetic BU, despite the significant operations, customer and product portfolio ongoing reorganisation.

dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet dercill itiatem cum que doluptur magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi The Group's orders provide an optimistic outlook for the year-end, which we believe can be extended into the first months of 2024." - Fine Foods & Pharmaceuticals N.T.M. S.p.A. CEO Giorgio Ferraris.

ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic

ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni tem etum laborat estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt, simus. The Group's 9M 2023 EBITDA was € 18.3 million compared to € 12.1 million in the same period of the previous year, showing an increase of 51.2%. Adjusted EBITDA for the period corresponds to EBITDA. In 9M 2022, Adjusted EBITDA was € 12.6 million.

Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur? Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea The Group's EBITDA Margin for the period, which coincided with the Adjusted EBITDA Margin, was approximately 10%, up from 7.9% in 2022. This increase can be attributed to the positive performance of the Food and Pharma BUs, which drive the Group's business, with a margin totalling 11.4%. The 9M 2022 adjusted EBITDA Margin was 8.2%.

archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. The margin improvement derived from the reduction in the impact of personnel and energy costs on revenues, and better absorption of fixed costs on revenues. However, the energy percentage cost is still higher than the historical cost. This impact is estimated at almost 1.7% on revenue, equal to about € 1.5 million, which would have brought EBITDA to € 19.8 million, with a margin of 10.7%.

Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea The Operating result (EBIT), which like EBITDA benefited from the improved margin of the main cost items in the first nine months, was € 2.2 million, up from € 1 million in the same period of 2022. Adjusted EBIT for the period was € 6.6 million compared to € 1.4 million in the same period of 2022.

iducienduci tore anda dolor sequi que acea dia deleniaspero core quis et laccaborenti doloraesecea vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro EBIT for 9M 2023 was affected by the above energy impact, net of which it would have been € 3.6 million and Adjusted EBIT € 8 million.

velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil id moluptatur. endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime eum quo qui quas aut ant ut laborporae. Ut porum et optates mi, ommolor eperit quiassequid earunde lluptate ditatur am ut qui as ut laut ditem laborporio molorem saperessi omnissusciis dolut magnihil ini corerro es niscia natem reri qui soloratistis velita quam volo quo el et alit The Income Before Taxes as of 30 September 2023 was € 0.5 million compared to € -11.6 million as of 30 September 2022. This result was almost entirely attributable to the impairment of Pharmatek's goodwill which was merged by incorporation into Euro Cosmetic and the increase in financial expenses. The combined effect of these negative changes and allocation of current taxes by the parent company Fine Foods of € 2.3 million led to a Result for the Period of € -1.8 million (€ -11.9 million as of 30 September 2022). The adjusted Result for the Period, net of the goodwill impairment, was € 2.6 million (€ -11.6 million as of 30 September 2022).

harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci. The result for both periods was also impacted by changes in the Fair Value of financial assets. As mentioned during the approval of the Directors' Report as of 30 June 2023, the securities portfolio was almost entirely

Role

Name Surname disposed of (one security of about € 98,000 remained). The income recorded in the income statement was final.

Company Tangible Fixed Assets increased by approximately € 1.7 million in 9M 2023, due to net investments of € 11.9 million and depreciation for the period of € 10.3 million.

Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil Intangible fixed assets and rights of use were € 16.8 million as of 30 September 2023 (€ 22.9 million at the end of FY 2022). This decrease was mainly due to the Pharmatek's goodwill impairment of € 4.4 million.

eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore Working capital as of 30 September 2023 was € 54.5 million (€ 44.2 million at the end of the previous financial year). The Commercial Net Working Capital of € 58.5 million (€ 46.3 million as of 31 December 2022), changed as follows: increase in trade receivables (€ 2.6 million), inventories (€ 6.9 million) and a decrease in trade payables (€ 2.7 million). These changes are mainly attributable to the increase in revenue as of 30 September 2023.

solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet dercill itiatem cum que doluptur Shareholders' Equity as of 30 September 2023 was € 128.8 million, down from 31 December 2022 (€ 133.3 million).

magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni tem etum laborat estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt, simus. Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. The Group's Net Financial Position as of 30 September 2023 was € 53.6 million, with a negative change of € 10 million compared to the NFP of € 43.6 million as of 31 December 2022 but with an improvement of approximately € 4.2 million compared to the figure as of 30 June 2023 (€ 57.8 million). The change was mainly due to the increase in Commercial Net Working Capital (12.2 million), change in net CAPEX made in the period (of about € 11.8 million), and the dividends distributed in H1 2023 (€ 2.5 million) which were partially offset by the positive effect of the result net of depreciation and amortisation (€ 14.4 million) and other minor changes of approximately € 2 million.

Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin SIGNIFICANT EVENTS OCCURRING AFTER 30 September 2023

cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. No specific events needed to be reported, except for what is mentioned in the Leakage Receivable paragraph of the Interim Financial Report as of 30 September 2023. After an in-depth discussion during the hearing of 7 November 2023, the judge adjourned the case to 5 March 2024 to attempt a conciliation between the parties. The judge further ordered a personal appearance, before deciding on the provisional enforceability of the Injunction Order.

Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma

Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur?

conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea BUSINESS OUTLOOK

iducienduci tore anda dolor sequi que acea dia deleniaspero core quis et laccaborenti doloraesecea vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil The most recent predictions are for a slowdown in global economic growth, impacted by high inflation, restrictive financing conditions and the geopolitical scenarios that are affecting Europe and the Middle East. The energy cost, although lower than in the previous period, remains significantly higher than historical trends.

id moluptatur. endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime eum quo qui quas aut ant ut laborporae. Ut porum et optates mi, ommolor eperit quiassequid Despite the complex international situation, the Group will develop the business along three main lines - Food, Pharma, and Cosmetics - by strengthening corporate functions' activities. Fine Foods will seize any opportunities for growth through external lines.

earunde lluptate ditatur am ut qui as ut laut ditem laborporio molorem saperessi omnissusciis dolut magnihil ini corerro es niscia natem reri qui soloratistis velita quam volo quo el et alit The increase in turnover recorded in the first nine months of the year confirmed the effectiveness of the commercial actions taken for the Food BU and allowed us to forecast a largely positive outlook.

harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci. The Pharma BU is expected to significantly grow due to the key multi-year agreements signed with important international customers that will require a production plant expansion.

Name Surname Role Company The integration and optimisation of processes will continue for the Cosmetic BU. Investments for the Trenzano site production capacity expansion are nearing completion. Efficiency is expected to improve when fully operational and customer demand response ability is expected to increase. The Cremosano plant was permanently closed and production transferred to Trenzano.

Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il Confirming what was highlighted in the half-year report, margins in the third quarter improved compared to the previous quarter. Considering the results achieved in the period after 30 September 2023, management is reasonably confident of the margin improvement trend, especially for the Food and Pharma BUs, despite the penalisation resulting from the Cosmetic BU due to reorganisation.

invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore The Groups believes in a fair and sustainable future, creating long-term value for the benefit of its stakeholders and contributing to the development and well-being of the communities in which it operates. Fine Foods has been a benefit corporation since April 2021. ESG issues for Fine Foods are a structured set of activities and the Group intends to continue its sustainability programme in the future.

solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet dercill itiatem cum que doluptur

***

magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni tem etum laborat estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt, simus. It should be noted that under Article 154-ter, paragraph 2, of Legislative Decree no. 58 of 24 February 1998, the Interim Financial Report as of 30 September 2023, approved by the Board of Directors on today's date, will be made available today to shareholders and the public at the registered office, on the Company's website at www.finefoods.it, Investor Relations/Financial Reports section, and the authorised storage system .

Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur? Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea Under Art. 154-bis, paragraph 2 of the Consolidated Law on Financial Intermediation, the Manager responsible for preparing the corporate financial reports, Pietro Bassani, declared that the accounting information contained in this press release corresponds to the document results, accounting books and records.

offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. This press release is available on the Fine Foods website www.finefoods.it, in the Investor Relations/Press Releases section.

Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma

***

archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo

conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea iducienduci tore anda dolor sequi que acea dia deleniaspero core quis et laccaborenti doloraesecea vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil id moluptatur. endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime eum quo qui quas aut ant ut laborporae. Ut porum et optates mi, ommolor eperit quiassequid earunde lluptate ditatur am ut qui as ut laut ditem laborporio molorem saperessi omnissusciis Fine Foods & Pharmaceuticals N.T.M. S.p.A., listed on Borsa Italiana's Euronext STAR Milan (Ticker: FF) is an Italian independent CDMO (Contract Development and Manufacturing Organisation) It develops and manufactures contract products for the pharmaceutical, nutraceutical and cosmetics industries. Founded in 1984, Fine Foods proved to be a reliable and capable strategic partner for customers in the reference sectors. The company's organisation can provide successful design process and solid, long-term partnerships. The continuous search for excellence is part of the company's business model and includes research and development, innovation, process reliability, product quality, ESG, and sustainable management of the Group's supply chain. Fine Foods is a benefit corporation which relies on certifications and ratings under international standards. These guarantee its sustainability commitment across the business. With € 207 million revenue in 2022 and more than 10 per cent CAGR over the last decade, Fine Foods is a growing and future-oriented company.

dolut magnihil ini corerro es niscia natem reri qui soloratistis velita quam volo quo el et alit

harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci.

simus.

id moluptatur.

Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil

Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero

Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat.

endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime

eum quo qui quas aut ant ut laborporae. Ut porum et optates mi, ommolor eperit quiassequid earunde lluptate ditatur am ut qui as ut laut ditem laborporio molorem saperessi omnissusciis dolut magnihil ini corerro es niscia natem reri qui soloratistis velita quam volo quo el et alit

harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci.

Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur? Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea iducienduci tore anda dolor sequi que acea dia deleniaspero core quis et laccaborenti doloraesecea vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil

eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il

maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet dercill itiatem cum que doluptur magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni tem etum laborat estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt,

invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat.

Name Surname Role Company For further information: Fine Foods & Pharmaceuticals N.T.M. S.p.A. Tel +39 035 4821382 Investor Relations: [email protected] Media Relations: [email protected]

Name Surname

Role

Consolidated income statement

Company	Nine Months	Nine Months
(amounts in € units)	30 September 2023	30 September 2022

Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil Revenues and income
eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il Revenues from contracts with customers	185,686,107	152,816,103
invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. Other revenues and income	1,387,036	326,276
Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero Total revenues	187,073,143	153,142,380
maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum
Operating costs facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore
Costs for consumption of raw materials, change in inventories of finished goods and work in progress. solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a	115,605,924	92,707,301
Personnel costs dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet	32,378,532 dercill itiatem cum que doluptur	28,249,926
Costs for services magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi	19,503,402	19,121,884
Other operating costs ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam	1,259,173	944,914
Amortisation, depreciation, and impairment losses estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic	16,158,322	11,133,814
Total operating costs ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni	184,905,353	152,157,839 tem etum laborat
Operating result estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt,	2,167,790	984,540
simus.
Changes in fair value of financial assets and liabilities	1,703,519	(7,885,713)
Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. Loss on financial receivables	-	(3,266,960)
Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur? Financial income	130,262	29,962
Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin Financial charges	(3,489,591)	(1,428,624)
cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea Income before taxes	511,980	(11,566,794)
archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo Income taxes	2,272,317	322,460
offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet Profit/(loss) for the financial year	(1,760,337)	(11,889,254)
haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus

plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma Consolidated comprehensive income statement

conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea iducienduci tore anda dolor sequi que acea dia deleniaspero core quis et laccaborenti doloraesecea (amounts in € units)	Nine Months 30 September 2023	Nine Months 30 September 2022
vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro Profit /(loss) for the financial year (A)	(1,760,337)	(11,889,254)
velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil Components that will not be subsequently reclassified to profit/(loss) for the financial year id moluptatur. Revaluation of net employee benefit liabilities/assets Tax effect endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime eum quo qui quas aut ant ut laborporae. Ut porum et optates mi, ommolor eperit quiassequid	(28,741) 6,898	324,505 (40,099)
Other comprehensive income (B) components earunde lluptate ditatur am ut qui as ut laut ditem laborporio molorem saperessi omnissusciis	(21,843)	284,406
dolut magnihil ini corerro es niscia natem reri qui soloratistis velita quam volo quo el et alit
Comprehensive profit/(loss) (A+B) harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci.	(1,782,180)	(11,604,848)

Consolidated statement of financial position

Name Surname (amounts in € units)	30 September 2023	31/12/2022
Role Assets
Company Non-current assets
Property, plant and machinery	105,860,709	104,162,050
Goodwill	11,507,954	15,907,954
Other intangible fixed assets Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil	1,702,836	1,780,551
Rights of use	3,544,680	5,163,111
eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il Other non-current assets	354,120	820,871
invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. Deferred tax assets	7,207,162	7,312,662
Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero Total non-current assets	130,177,461	135,147,200
maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum Current assets
Inventories facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore	47,280,841	40,422,499
Trade receivables solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a	41,915,900	39,347,321
Tax receivables	242,498	2,268,044
dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet Other current assets	dercill itiatem cum que doluptur 7,930,244	5,890,398
magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi Current financial assets	3,832,943	66,512,584
ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam Cash and other liquid assets	41,274,454	10,232,262
Total current assets estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic	142,476,881	164,673,109
ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni		tem etum laborat
Total assets estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt,	272,654,342	299,820,309
simus.
Shareholders' equity
Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. Share Capital	22,770,445	22,770,445
Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur? Other reserves	114,285,845	126,461,456
Employee benefit reserve Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin	184,343	206,186
FTA reserve cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea	(6,669,789)	(6,669,789)
Profits carried forward archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo	22,610	22,610
Profit/(loss) for the financial year offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet	(1,760,337)	(9,501,145)
Total Shareholders' Equity	128,833,117	133,289,763
haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus Non-current liabilities
plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. Bonds		-
Non-current bank borrowings Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same	63,265,879	77,573,797
Employee benefits nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma	2,217,111	2,419,013
Provision for risks and charges conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea	3,705	41,105
Provision for deferred taxes iducienduci tore anda dolor sequi que acea dia deleniaspero core quis et laccaborenti doloraesecea	252,741	240,553
Non-current lease payables	1,084,363	2,222,216
vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro Total non-current liabilities	63,265,879	82,496,684
Current liabilities velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia	3,332,679	3,323,051
Bonds con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil	30,614,960	36,590,346
Current bank borrowings id moluptatur.	30,724,361	33,450,468
Trade payables endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime	778,798	-
Taxes payable eum quo qui quas aut ant ut laborporae. Ut porum et optates mi, ommolor eperit quiassequid	420,214	651,576
Current lease payables	11,126,415	10,018,421
earunde lluptate ditatur am ut qui as ut laut ditem laborporio molorem saperessi omnissusciis Other current liabilities	76,997,427	84,033,862
Total current liabilities dolut magnihil ini corerro es niscia natem reri qui soloratistis velita quam volo quo el et alit
harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci. Total Shareholders' equity and Liabilities	272,654,342	299,820,309

Fine Foods & Pharmaceuticals N.T.M. S.p.A. Via Berlino, 39 Zingonia-Verdellino 24040 (BG) Italia T. +39 035 4821382 [email protected]

CF / P.IVA IT 09320600969 CAP. SOC. € 22.770.445,02 FINEFOODS.IT

Consolidated cash flow statement

Name Surname	30 September 2023	30 September 2022
Role PROFIT/(LOSS) FOR THE FINANCIAL YEAR	(1,760,337)	(11,889,254)
Company Adjustments to reconcile profit after tax with net cash flows:
Depreciation and impairment of property, plant and machinery	10,340,729	9,756,099
Amortisation and impairment of intangible fixed assets	636,454	643,726
Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil Amortisation of rights of use	781,138	733,989
eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il Other write-downs of fixed assets	4,400,000	-
invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. Impairment of financial receivables	-	3,266,960
Financial income Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero	(130,262)	(29,962)
Financial charges maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum	3,480,553	1,385,843
Changes in fair value of financial assets and liabilities facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore	(1,703,519)	7,885,713
Financial charges on financial liabilities for leases solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a	9,038	42,781
Income taxes dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet	2,148,001 dercill itiatem cum que doluptur	(32,753)
Gains on the disposal of property, plant and machinery magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi	(99,036)	(36,492)
Current assets write-downs ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam	81,232	681,515
Net change in severance indemnity and pension funds	(282,368)	(154,123)
estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic Net change in provisions for risks and charges	(37,400)	150,000
ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni Net change in deferred tax assets and liabilities	124,315	tem etum laborat 362,992
estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt, Interest paid	(3,310,467)	-
simus. Income taxes paid	-	-
Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. Changes in net working capital:
Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur? (Increase)/decrease in inventories	(6,739,349)	(8,075,510)
Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin (Increase)/decrease in trade receivables	(2,768,803)	(9,696,571)
cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea (Increase)/decrease in other non-financial assets and liabilities	128,370	4,563,141
archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo Disposal of assets held for sale	-	-
offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet Increase/(decrease) in trade payables	(2,726,107)	(1,802,758)
haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus NET CASH FLOWS FROM OPERATING ACTIVITIES	2,572,183	(3,621,712)
plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. Investments:
Investments in tangible fixed assets Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same	(12,465,732)	(11,092,500)
Disposal of tangible fixed assets nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma	521,062	156,181
Investments in intangible fixed assets conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea	(558,740)	(541,538)
Net (investments)/disposals in financial assets iducienduci tore anda dolor sequi que acea dia deleniaspero core quis et laccaborenti doloraesecea	52,383,160	416,796
NET CASH FLOWS FROM INVESTMENTS vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro	39,879,750	(11,061,062)
Financing: velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia
New financing con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil	27,110,914	72,650,407
Funding repayment id moluptatur.	(35,314,267)	(55,637,508)
Principal payments - lease liabilities endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime	(531,922)	(711,991)
Dividends paid to the parent company's shareholders	(2,452,708)	(3,866,869)
eum quo qui quas aut ant ut laborporae. Ut porum et optates mi, ommolor eperit quiassequid Sale/(purchase) of treasury shares	(221,758)	(811,452)
earunde lluptate ditatur am ut qui as ut laut ditem laborporio molorem saperessi omnissusciis CASH FLOWS FROM FINANCING	(11,409,741)	11,622,588
dolut magnihil ini corerro es niscia natem reri qui soloratistis velita quam volo quo el et alit NET CHANGE IN CASH AND CASH EQUIVALENTS	31,042,192	(3,060,186)
harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci. Cash and short-term deposits as of 1 January	10,232,262	17,118,957
Cash and short-term deposits as of 30 September	41,274,454	14,058,769

Fine Foods & Pharmaceuticals N.T.M. S.p.A. Via Berlino, 39 Zingonia-Verdellino 24040 (BG) Italia T. +39 035 4821382 [email protected]

CF / P.IVA IT 09320600969 CAP. SOC. € 22.770.445,02 FINEFOODS.IT

Name Surname

id moluptatur.

Role

Consolidated Shareholders' equity changes

Company Mus. Optas maximus et eatiur aut	Share Capital il , tem rehenem	Legal reserve ium et . Itati	Negative reserve for treasury shares in the a nestorem portfolio volut	Merger surplus reserve acese laudisi	Share premium reserve tatur,	Extraordinary reserve aut que eost il mil	Other reserves hil il	FTA reserve	Employee benefit reserve	Profits/losses carried forward	Profit/loss for the financial year	Total Shareholders' equity
doluptur rest, invenducilla esse pra con pliquun Balance as of 1 January 2023	volorpo tiatur , te 22,770,445	volorer 5,000,000	ovidund (13,680,454)	eaque estiist electium 29,741,389	pediscipsum resciat 86,743,750	ipsam 14,240,490	4,416,281	(6,669,789)	206,186	22,610	(9,501,145)	133,289,763
Atiosa poribus autatem	ellaccum	, sum secto	vellatiam	, utaturiorum		am, quat	quaspero
maio . Temperum harum qui Profit/(loss) for the financial year	conem a abor to	sunt,	odi atureic	temo	esciaspedis	quiassum	eum				(1,760,337)	(1,760,337)
facitas mi , sint , ommoluptatur Other income statement components	pernatiist aut	fugia	quidene	modioriatium	facepudis	ommolore ut			(21,843)			(21,843)
solupta quiducilles erspis Comprehensive profit/(loss) dolenimilit lam as volo quid	magnam ium et eossincium , ut	ad labo	earchit atioremqui . Ehendicat officet	dercill	hit arum sunt itiatem	, qui sin nost cum que doluptur	a		(21,843)	-	(1,760,337)	(1,782,180)
magnihi odi voluptia ciurit Dividends ut que sumquam, tem aut IRS derivatives provision	venimol ipsum nonem est	ecaesen delesen lit	desciae inihita mo qui	caborit nobis	enimetureped enturibusam	quidel (2,452,708) velent	modi quam					(2,452,708) -
abo alis . Ut estrumetur eum as et Purchase of treasury shares	esti sit	harum ut	eum aut (221,759)	eaquis is	repti cust	abore ni	omnihic					(221,759)
am dolupid digent ipiciet quia 2022 profit allocation quodic iuntest estrum tet	fugias eostia , quo omnimus	reptas	nossecus, invero eosapitiis	od essit i , dolupta tecullam	officeni eum, od	tem etum (9,501,145) modipissunt	laborat ,				9,501,145	-
simus Balance as of 30 September 2023 eum faciden Mo el	22,770,445 imusam et aut	5,000,000 volupta	(13,902,213) turepedi	29,741,389 cus verum adis	86,743,750 nobit	2,286,638 doluptat	4,416,281	(6,669,789)	184,343	22,610	(1,760,337)	128,833,116

haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. Fine Foods & Pharmaceuticals N.T.M. S.p.A. Via Berlino, 39 Zingonia-Verdellino 24040 (BG) Italia T. +39 035 4821382 [email protected]

endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime

harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci.

nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea iducienduci tore anda dolor sequi que acea dia deleniaspero core quis et laccaborenti doloraesecea vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil

Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same CF / P.IVA IT 09320600969 CAP. SOC. € 22.770.445,02 FINEFOODS.IT

AI Terminal

Fine Foods & Pharmaceuticals Ntm

4495_rns_2023-11-14_b1945eb5-1ae7-4a94-887a-678540b0198f.pdf

Name Surname The Board of Directors of Fine Foods & Pharmaceuticals N.T.M. S.p.A. today approved the Group's Interim Financial Report as of 30 September 2023.

Company Consolidated revenue +21.5% and EBITDA +51.2% in the first nine months of 2023

Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum Highlights

Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin SIGNIFICANT EVENTS OCCURRING AFTER 30 September 2023

conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea BUSINESS OUTLOOK

Consolidated income statement

Consolidated statement of financial position

Consolidated cash flow statement

Consolidated Shareholders' equity changes

More from Fine Foods & Pharmaceuticals Ntm

Talk to a Data Expert